Advertisement

Combined Modality Treatment of Small-Cell Lung Cancer

  • Julie R. Brahmer
  • Larry Kleinberg
  • David S. Ettinger
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Small-cell lung cancer (SCLC) accounts for approx 18–25% of the estimated 169,500 cases of lung cancer in 2001 (1,2). Most patients present with metastatic disease due to the aggressive nature of SCLC. SCLC is staged using a two-stage system identified by the Veterans Administration Lung Group (VALG). The VALG classified limited-stage disease (LD) as tumor limited to one hemithorax and its regional lymph nodes that can be encompassed by one radiation port. LD accounts for approx 40% of all SCLC cases. Extensive-stage disease (ED) is tumor spread beyond these boundaries (2). The presence of pleural effusions and/or supraclavicular lymphadenopathy have been considered LD by some investigators and ED by others.

Keywords

Clin Oncol Radiat Oncol Biol Phys Local Recurrence Rate Complete Response Rate Prophylactic Cranial Irradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cancer Facts and Figures, 2001. Atlanta: American Cancer Society, 14.Google Scholar
  2. 2.
    Murran J, Glatstein E, Pass HI. Small-cell Lung Cancer. In: ( Devita VT Jr, Hellman S, Rosenberg SA eds). Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: JB Lippincott, 2001: 983–1018.Google Scholar
  3. 3.
    Birch R, Omura GA, Greco FA, et al. Patterns of failure in combined chemotherapy and radiotherapy for limited small-cell lung cancer: Southeastern Cancer Study Group experience. NCI Monogr 1988; 6: 265–270.PubMedGoogle Scholar
  4. 4.
    Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316: 912–918.PubMedCrossRefGoogle Scholar
  5. 5.
    Kies MS, Mira JG, Crowley JJ, et al. Multimodal therapy for limited small-cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders, and with wide-field vs reduced-field radiation in partial responders: A Southwest Oncology Group Study. J Clin Oncol 1987; 5: 592–600.PubMedGoogle Scholar
  6. 6.
    Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993; 11: 336–344.PubMedGoogle Scholar
  7. 7.
    Creech R, Richter M, Finkelstein D, for the ECOG. Combination chemotherapy with or without consolidation radiation therapy (RT) for regional small-cell carcinoma of the lung (abstract 756). Proc Am Soc Clin Oncol 1988; 7: 196.Google Scholar
  8. 8.
    Baldeyrou P, Marrash R, LeChevalier R, Arriagada R. L’endoscopie bronchique dans le bilan diagnostique et evolutif des concers broncho-pulmonaires a petites cellules. Bull Cancer 1987; 74: 511–515.PubMedGoogle Scholar
  9. 9.
    Schwartz JL, Rotmensch J, Beckett MA, et al. X-ray and cis-diamminedichloroplatinum (II) cross-resistance in human tumor cell lines. Cancer Res 1988; 48: 5133–5135.PubMedGoogle Scholar
  10. 10.
    World Health Organization: Histologic typing of lung tumors, 2nd ed. Geneva: World Health Organization, 1981.Google Scholar
  11. 11.
    Hirsch FR, Matthews MJ, Aisner S, et al. Histopathologic classification of small-cell lung cancer. Changing concepts and terminology. Cancer 1988; 62: 973.PubMedCrossRefGoogle Scholar
  12. 12.
    Aisner SC, Finkelstein DM, Ettinger DS, et al. The clinical significance of variant-morphology small-cell carcinoma of the lung. J Clin Oncol 1990; 8: 402.PubMedGoogle Scholar
  13. 13.
    Fraire AE, Johnson EH, Yesner R, et al. Prognostic significance of histopathologic subtype and stage in small-cell lung cancer. Hum Pathol 1992; 23: 520.PubMedCrossRefGoogle Scholar
  14. 14.
    Mangum MD, Greco FA, Hainsworth JD, et al. Combined small-cell and non-small-cell lung cancer. J Clin Oncol 1989; 7: 607.PubMedGoogle Scholar
  15. 15.
    Brigham BA, Bunn PA, Minna JD, Cohen MH, Ihde DC, Shachney SE. Growth rates of small-cell bronchogenic carcinomas. Cancer 1978; 42: 2880–2886.PubMedCrossRefGoogle Scholar
  16. 16.
    Charbit A, Malaise EP, Tubiana M. Relation between the pathological nature and the growth rate of human tumors. Eur J Cancer 1977; 7: 307–315.Google Scholar
  17. 17.
    Straus MJ. Characteristics of lung cancer. In: Straus MJ, ed. Lung cancer; clinical diagnosis and treatment. New York: Grune & Stratton, 1977: 19–32.Google Scholar
  18. 18.
    Hansen HH. Management of small-cell cancer of the lung. Lancet 1992; 339: 846–849.PubMedCrossRefGoogle Scholar
  19. 19.
    Arriagada R, LeChevalier TL. Regional disease. In: ( Aisner J, Arriagada R, Green MR, Martini N, Perry MC eds). Comprehensive textbook of thoracic oncology. Baltimore: Williams & Wilkins, 1996: 456–495.Google Scholar
  20. 20.
    Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus: Ten-year follow-up. Lancet 1973; 2: 63–65.PubMedCrossRefGoogle Scholar
  21. 21.
    Mountain CF. Clinical biology of small-cell carcinoma: Relationship to surgical therapy. Semin Oncol 1978; 5: 272–279.PubMedGoogle Scholar
  22. 22.
    Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 1969; 46: 516–525.PubMedCrossRefGoogle Scholar
  23. 23.
    Bunn PA, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited small-cell lung cancer. A prospective, randomized trial. Ann Intern Med 1987; 106: 655–662.PubMedGoogle Scholar
  24. 24.
    Pignon JP, Arriagada R, Ihde D, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 1618–1624.PubMedCrossRefGoogle Scholar
  25. 25.
    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell lung cancer? A meta-analysis. J Clin Oncol 1992; 10: 890–895.PubMedGoogle Scholar
  26. 26.
    Jenkin D, Chan H, Freedman J, et al. Hodgkin’s disease in children: treatment results with MOPP and low-dose, extended-field irradiation. Cancer Treat Rep 1982; 66: 949–959.PubMedGoogle Scholar
  27. 27.
    Bergsagel DE, Phil D, Jenkin RDT, et al. Lung cancer: clinical trial of radiotherapy alone versus radiotherapy plus cyclophosphamide. Cancer 1972; 30: 621–627.PubMedCrossRefGoogle Scholar
  28. 28.
    Turrisi A, Glover DJ. Thoracic radiotherapy variables: influence on local control in small-cell lung cancer limited disease. Int J Radiat Oncol Biol Phys 1990; 19: 1473–1479.PubMedCrossRefGoogle Scholar
  29. 29.
    Choi N, Carey R. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma: an update. Int J Radiat Oncol Biol Phys 1989; 17: 307–310.PubMedCrossRefGoogle Scholar
  30. 30.
    Coy P, Hodson BM, Payne D, et al. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small-cell lung cancer. Initial results of a Canadian multicenter randomized trial. Int J Radiat Oncol Biol Phys 1987; 14: 219–226.CrossRefGoogle Scholar
  31. 31.
    Choi NC, Herndon JE II, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998; 16: 3528–3536.PubMedGoogle Scholar
  32. 32.
    Turrisi A, Glover DJ, Mason B, et al. Long term results of platinum etoposide (PE) + twice daily thoracic radiotherapy (TRT) for limited small-cell lung cancer (abstract 975). Proc Am Soc Clin Oncol 1995; 14: 363.Google Scholar
  33. 33.
    Armstrong JG, Rosenstein MM, Kris MG, et al. Twice daily thoracic irradiation for limited small-cell lung cancer. Int J Radiat Oncol Biol Phys 1991; 21: 1269–1274.PubMedCrossRefGoogle Scholar
  34. 34.
    Johnson BE, Salem C, Nesbit J, et al. Limited stage small-cell lung cancer (SCLC) treated with concurrent BID chest radiotherapy (RT) and etoposide, cisplatin (VP/PT) followed by chemotherapy (CT) selected by in vitro drug sensitivity testing (abstract 818). Proc Am Soc Clin Oncol 1991; 10: 240.Google Scholar
  35. 35.
    Tunisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265–271.CrossRefGoogle Scholar
  36. 36.
    Kumar P. The role of thoracic radiotherapy in the management of limited-stage small-cell lung cancer. Chest 1997; 112 (Suppl): 2595–2665.CrossRefGoogle Scholar
  37. 37.
    Bleehen NM. Radiotherapy for small-cell lung cancer. Chest 1986; 89: 268S - 276S.PubMedGoogle Scholar
  38. 38.
    Choi NC. Reassessment of the role of radiation therapy relative to other treatments in small-cell carcinoma of the lung. In: ( Choi NC, Grillo HC, eds). Thoracic oncology. New York: Raven Press, 1983: 233–256.Google Scholar
  39. 39.
    Liengswangwong V, Bonner J, Shaw E, et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 1994; 12: 496–502.PubMedGoogle Scholar
  40. 40.
    Brodin O, Rikner G, Steinholz L, et al. Local failure in patients treated with radiotherapy and multidrug chemotherapy for small-cell lung cancer. Acta Oncol 1990; 29: 739–746.PubMedCrossRefGoogle Scholar
  41. 41.
    Arriagada R, Pellac-Cosset B, Cueto Ladron de Guevara J, et al. Alternating radiotherapy and chemotherapy schedules in limited small-cell lung cancer: analyses of local chest recurrences. Radiother Oncol 1991; 20: 91–98.PubMedCrossRefGoogle Scholar
  42. 42.
    Auquier A, Rutqvist LE, Rotstein S, Arriogada R. Post-mastectomy megavoltage radiotherapy: the Oslo and Stockholm trials. Eur J Cancer 1992; 28: 433–437.PubMedCrossRefGoogle Scholar
  43. 43.
    Tubiana M, Arriagada R, Cosset JM. Optimizing combinations of drugs and radiation. The interdigitated alternating regimen. In: ( Wither HR, Peters LJ, eds). Innovations in radiation oncology. Berlin: Springer-Verlag, 1988: 265–276.CrossRefGoogle Scholar
  44. 44.
    Ensley JF, Jacobs JR, Weaver A, et al. Correlation between response to cis-platinum combination and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984; 54: 811–814.PubMedCrossRefGoogle Scholar
  45. 45.
    Carlson RW, Sikic BI, Gandara DR, et al. Late consolidative radiation therapy in the treatment of limited-stage small-cell lung cancer. Cancer 1991; 68: 948–958.PubMedCrossRefGoogle Scholar
  46. 46.
    Lebeau B, Chastang C, Brechot JM, et al. A randomized trial of delayed thoracic radiotherapy in complete responder patients with small-cell lung cancer: Petites Cellules Group. Chest 1993; 104: 726–733.PubMedCrossRefGoogle Scholar
  47. 47.
    Takada M, Fukuoka M, Furuse K, et al. A Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: preliminary results of the Japan Clinical Oncology Group (abstract 1103). Proc Am Soc Clin Oncol 1996; 15: 372.Google Scholar
  48. 48.
    Lebeau B, Urban T, Brechot JM, et al. A randomized clinical trial comparing concurrent and alternated thoracic irradiation for patients with limited small-cell lung carcinoma. Cancer 1999; 86: 1480–1487.PubMedCrossRefGoogle Scholar
  49. 49.
    Perry MC, Herndon JE, Eaton WL, et al. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B study 8083. J Clin Oncol 1998; 16: 2466–2467.PubMedGoogle Scholar
  50. 50.
    Work E, Nielsen OK, Bentzen SM, et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. J Clin Oncol 1997; 15: 3030–3037.PubMedGoogle Scholar
  51. 51.
    Gregor A, Drings P, Burghouts J, et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group study. J Clin Oncol 1997; 15: 2840–2849.PubMedGoogle Scholar
  52. 52.
    Jeremic B, Shibamoto Y, Acimovic L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997; 15: 893–900.PubMedGoogle Scholar
  53. 53.
    Glisson B, Scott C, Komaki R, et al. Cisplatin, Ifosfamide, prolonged oral etoposide and concurrent accelerated hyperfractionated thoracic radiotherapy for patients with limited small-cell lung cancer: results of RTOG 93–12 (abstract 1733). Proc Am Soc Clin Oncol 1998; 17: 450a.Google Scholar
  54. 54.
    Ettinger DS, Seiferheld WF, Abrams RA, et al. Cisplatin, etoposide, paclitaxel and concurrent hyperfractionated thoracic radiotherapy for patients with limited disease small-cell lung cancer: Preliminary results of RTOG 96–09 (abstract 1917). Proc Am Soc Clin Oncol 2000; 19: 490a.Google Scholar
  55. 55.
    Sandler A, Declerck L, Wagner N, et al. A phase II study of cisplatin plus etoposide plus paclitaxel and concurrent radiation therapy for previously untreated limited stage small-cell lung cancer (E2596): An Eastern Cooperative Oncology Group trial (abstract 1920). 2000; 19:491a.Google Scholar
  56. 56.
    Glisson BS, Lee JS, Shin DM, et al. Topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic radiation in patients with limited small-cell lung cancer (abstract 1929 ). 2000; 19: 493a.Google Scholar
  57. 57.
    Lyss JE, Herndon JE, Bogart D, et al. Topotecan (Topo) + Paclitaxel (Tax) + G-CSF Induction followed by concurrent chemoradiotherapy for patients with limited stage small-cell lung cancer: preliminary analysis of CALGB 39808 (abstract 1270). Proc Am Soc Clin Oncol 2001; 20: 318a.Google Scholar
  58. 58.
    Gregor A. Prophylactic cranial irradiation in small-cell lung cancer: Is it ever indicated ? Oncology 1998; 12: 19–24.PubMedGoogle Scholar
  59. 59.
    Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Nat Cancer Inst 1995; 87: 183–190.PubMedCrossRefGoogle Scholar
  60. 60.
    Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation as indicated following complete response to induction therapy in small-cell lung cancer: Results of a multicentre randomized trial. Eur J Cancer 1997; 33 (Supp1 1): 1752–1758.PubMedCrossRefGoogle Scholar
  61. 61.
    Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation in patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341: 476–484.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Julie R. Brahmer
  • Larry Kleinberg
  • David S. Ettinger

There are no affiliations available

Personalised recommendations